Proteome Sciences PLC Notice of Results (7859S)
14 Marzo 2019 - 01:01AM
UK Regulatory
TIDMPRM
RNS Number : 7859S
Proteome Sciences PLC
14 March 2019
14 March 2019
Proteome Sciences plc
("Proteome Sciences" or the "Company")
Notice of Results
The Directors of Proteome Sciences look forward to updating
shareholders on the Company's performance, and on the outlook for
2019, at the time of announcing the 2018 full year results which
are scheduled for release on 2 April 2019.
Annual General Meeting
The Annual General Meeting of the Company will take place at the
offices of Allenby Capital, 5 St Helen's Place, London EC3A 6AB, at
2.30pm on 30 April 2019. Formal notice of such will be posted to
shareholders with the annual report in April.
For further information please contact:
Proteome Sciences plc
Dr Jeremy Haigh, Chief Executive Officer Tel: +44 (0)20 7043 2116
Dr Ian Pike, Chief Scientific Officer
Richard Dennis, Chief Commercial Officer
Allenby Capital Limited (AIM Nominated Adviser & Broker)
John Depasquale / Jeremy Porter Tel: +44 (0) 20 3328 5656
About Proteome Sciences plc. (www.proteomics.com)
Proteome Sciences plc is a specialist provider of contract
proteomics services to enable drug discovery, development and
biomarker identification, and employs proprietary workflows for the
optimum analysis of tissues, cells and body fluids. SysQuant(R) and
TMT(R)MS2 are unbiased methods for identifying and contextualising
new targets and defining mechanisms of biological activity, while
analysis using Super-Depletion and TMTcalibrator(TM) provides
access to over 8,500 circulating plasma proteins for the discovery
of disease-related biomarkers. Targeted assay development using
mass spectrometry delivers high sensitivity, interference-free
biomarker analyses in situations where standard ELISA assays are
not available.
The Company has its headquarters in London, UK, with laboratory
facilities in Frankfurt, Germany.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NORZXLFFKXFXBBZ
(END) Dow Jones Newswires
March 14, 2019 03:01 ET (07:01 GMT)
Proteome Sciences (LSE:PRM)
Gráfica de Acción Histórica
De Feb 2024 a Mar 2024
Proteome Sciences (LSE:PRM)
Gráfica de Acción Histórica
De Mar 2023 a Mar 2024